thymosin beta-4 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
=== Regulatory steps === Food may be contaminated during all stages of food production and retailing. In order to prevent viral contamination, regulatory authorities in Europe have enacted several measures:
Frittola (frittula in Palermitan dialect) is a traditional Sicilian street food from the Palermo region of Italy. It is similar to the frittole from Reggio Calabria, but seems to use calf parts instead of pig. The waste left from the slaughter of mechanically processed calves includes bones that are ground for industrial use, and pieces of meat boiled at high temperature in large silos. After the meat is cooked it is pressed to remove moisture and formed into bales. This process, similar to lyophilization (freeze drying), can preserve the frittoli for years. The frittularu "revives" the frittoli by frying it with lard and placing it in a large wicker basket (the panaru) and a cloth of flavorings such as bay leaf, and pepper. It is served by hand and placed on a sheet of waxed paper or in a bun or focaccia. Frittola was once transported by donkey, but is now sold from three-wheeled vans. One author describes the dish as "oil fried fat and cartilage". An 1869 book reports frittola in Venice, although this most likely refers to a sweet or savoury fried dough rather than the meaty version from Palermo.
=== Chromatography papers === Chromatography is a method chemists use to separate compounds. This type of filter paper has specific water flow rate and absorption speed to maximize the result of paper chromatography. The absorption speed of this type of filter paper is from 6 cm to 18 cm and the thickness is from 0.17 mm from 0.93 mm.
Sources: en.wikipedia.org
==== Monazite age mapping ==== Estimated ages are calculated across the compositional map by analysing the concentration of Th, Pb and U by the total-Pb dating method. The result is then used to generate an age map which approximately identifies all the age domains.
Soviet territorial demands to Turkey regarding the Dardanelles in the Turkish Straits crisis and Black Sea border disputes were also a major factor in increasing tensions. In September, the Soviet side produced the Novikov telegram, sent by the Soviet ambassador to the US but commissioned and "co-authored" by Vyacheslav Molotov; it portrayed the US as being in the grip of monopoly capitalists who were building up military capability "to prepare the conditions for winning world supremacy in a new war". On 6 September 1946, James F. Byrnes delivered a speech in Germany repudiating the Morgenthau Plan (a proposal to partition and de-industrialize post-war Germany) and warning the Soviets that the US intended to maintain a military presence in Europe indefinitely. As Byrnes stated a month later, "The nub of our program was to win the German people ... it was a battle between us and Russia over minds ..." In December, the Soviets agreed to withdraw from Iran after persistent US pressure, an early success of containment policy. By 1947, US president Harry S. Truman was outraged by the perceived resistance of the Soviet Union to American demands in Iran, Turkey, and Greece, as well as Soviet rejection of the Baruch Plan on nuclear weapons. In February 1947, the British government announced that it could no longer afford to finance the Kingdom of Greece against the Communist-led DSE in the Greek Civil War. In the same month, Stalin conducted the rigged 1947 Polish legislative election which constituted an open breach of the Yalta Agreement.
=== Harm reduction === Harm reduction programs operate under the understanding that certain levels of drug use are inevitable and focus on minimizing adverse effects associated with drug use. In the context of the opioid epidemic, harm reduction strategies are designed to improve health outcomes and reduce overdose deaths. Because many pain sufferers are also depressed, a challenge of harm reduction is that some applications, such as the use of drugs to reverse or avoid opioid overdose can nullify the effects of antidepressant medications which depend on the natural human opioid system. One of the first serious efforts to spread the harm reduction practices to combat heroin overdoses in American and beyond occurred in a conference in Seattle in January 2001 called "Preventing Heroin Overdose: Pragmatic Approaches." The conference was co-sponsored by the Alcohol and Drug Abuse Institute at the University of Washington and the Lindesmith Center (later known as the Drug Policy Alliance), which was led by Ethan Nadelmann, financed by George Soros, and aimed to end the war on drugs and promote harm reduction. The conference brought "scholars, researchers, doctors and other health care providers, drug-treatment providers and a handful of police officials" from across North America and Europe together to discuss approaches in combatting heroin overdoses.
=== Pleurotus ostreatus === The commonly known fungal species, white-rot basidiomycetes, are capable of degrading polymeric carbohydrates and using them for growth. Pleurotus ostreatus is an edible white-rot fungus known to degrade cellulose, hemicellulose and lignin, hence reinforcing its potential to thrive on wastes such as wood, textile, and agricultural residues. The growth of P. ostreatus on textile residue and mycelium production was tested in the department of civil engineering in Ontario Canada. The conducted experiment proved the applicability of textile waste as a potential feedstock. However, the loss in biocomposite weight of 1%–5% has been further corroborated by the water loss in the sample and in fungal mycelium. Additionally, the maximum compressive strength was observed as 270 kPa using cotton-based biocomposite. Overall, a lightweight biocomposite was obtained which could be a potential alternative for polystyrene- based products. These findings show the ability of the fungus to thrive on polyester plastic in textiles and provide an alternative for converting this plastic material into bio-based materials. Additionally, by varying the mycelium growth, the plasticity and stiffness properties of the resultant biocomposite can be changed.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.